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Abstract
Recent clinical data support the clinical use of oral lavender oil in patients suffering from subsyndromal anxiety. We
identified the molecular mechanism of action that will alter the perception of lavender oil as a nonspecific ingredient of
aromatherapy to a potent anxiolytic inhibiting voltage dependent calcium channels (VOCCs) as highly selective drug target.
In contrast to previous publications where exorbitant high concentrations were used, the effects of lavender oil in
behavioral, biochemical, and electrophysiological experiments were investigated in physiological concentrations in the
nanomolar range, which correlate to a single dosage of 80 mg/d in humans that was used in clinical trials. We show for the
first time that lavender oil bears some similarities with the established anxiolytic pregabalin. Lavender oil inhibits VOCCs in
synaptosomes, primary hippocampal neurons and stably overexpressing cell lines in the same range such as pregabalin.
Interestingly, Silexan does not primarily bind to P/Q type calcium channels such as pregabalin and does not interact with
the binding site of pregabalin, the a2d subunit of VOCCs. Lavender oil reduces non-selectively the calcium influx through
several different types of VOCCs such as the N-type, P/Q-type and T-type VOCCs. In the hippocampus, one brain region
important for anxiety disorders, we show that inhibition by lavender oil is mainly mediated via N-type and P/Q-type VOCCs.
Taken together, we provide a pharmacological and molecular rationale for the clinical use of the oral application of lavender
oil in patients suffering from anxiety.
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Introduction
Lavender oil (LA) is an important part of our today’s
aromatherapy to promote ‘‘well-being’’ and to reduce distress
and ‘‘ill-being’’. ‘‘Well-being’’ is a psychological construct com-
prising several domains related to personality including self-
acceptance and purpose in life among others [1]. Thus, changes
induced by LA might be more directed to improvement of ill-being
and distress which show overlap with anxiety and tension at the
biological level [2]. When applied by inhalation LA has been
associated not only with feelings of pleasantness but also with some
improving effects on mood and anxiety [3,4]. While most if not all
of those effects of lavender oil in aromatherapy may be mediated
by its pleasant odour there is increasing evidence strongly
suggesting a pharmacodynamic effect of LA independent of its
odour when applied systemically. I) Anxiolytic properties have
been demonstrated for LA in experimental animals following
inhalation of very high concentrations but also after i.p. or oral
administration [5–8]. II) When given in capsules containing 100 or
200 ml LA, anxiolytic properties have been shown in human
volunteers following stressful situations [9]. III) Recent clinical
trials using Silexan, a standardized LA oil preparation, showed
pronounced effects in patients with subsyndromal or subthreshold
anxiety disorders as well as in patients with Generalized Anxiety
Disorder (GAD) after oral administration. Importantly, Silexan
was similarly active compared to the benzodiazepine lorazepam
(0,5 mg) during 6 weeks of treatment [10] in patients suffering
from GAD. Silexan is a patented active substance produced from
Lavandula angustifolia flowers by steam distillation consisting of
the main active constituents. linalool (36.8%) and linalyl acetate
(34.2%). Silexan (active substance of LaseaH, available as
immediate release soft gelatine capules containing 80 mg) has
been licensed in Germany for the oral treatment of subsyndromal
anxiety and tension in 2009.
Even if several preclinical behavioural pharmacological studies
and the new clinical data clearly show the anxiolytic activity of LA
and especially of Silexan, the molecular mechanism of action
explaining these positive effects was missing. In contrast to
previous studies, we used physiological relevant concentrations of
Silexan which where found in pharmacokinetic experiments. First,
we showed anxiolytic effects of Silexan at these low concentrations
in behavioural pharmacological tests such as the elevated plus
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established anxiolytics diazepam and pregabalin. To decipher the
molecular mechanism of Silexan, we tested whether Silexan
modulates the activity of voltage operated calcium channels
(VOCCs) since Silexan did not reveal any affinity to known targets
of other anxiolytic drugs (SERT, NET, DAT, MAO-A and the
GABAA-receptor; data not shown). Under pathological conditions
like anxiety or stress disorders, it has been speculated that
enhanced Ca
2+-influx mainly through N and P/Q type VOCCs
may increase the release of neurotransmitters such as glutamate
and norepinephrine [11,12] which are involved in the pathogen-
esis of these diseases. Third, we show for the first time that Silexan
unselectively inhibits several VOCCs, such as P/Q-type and N-
type VOCCs using a broad set of methods including calcium
imaging as well as patch clamp technique. In addition, we were
able to demonstrate that Silexan does not bind to the binding site
of pregabalin at the P/Q type calcium channels. Pregabalin
modulates P/Q type VOCCs after binding at the auxiliary a2d-1
or -2 subunits and thereby reduces Ca
2+-influx through these
channels [13,14]. Taken together, we elucidate the anxiolytic
mechanism of action of LA and thereby provide a molecular
rationale for the clinical use of Silexan.
Materials and Methods
Animals
Female 2–3 months old NMRI mice with an average weight of
30 g were used for the preparation of synaptosomes, purified
synaptosomal membranes and for the determination of pentobar-
bital sleep time. Male 2–3 months old NMRI mice were utilized
for the elevated plus maze test. For the preparation of primary
hippocampal neurons female time-mated Sprague-Dawley rats
were used. Animals were purchased from Charles River Labora-
tories, Sulzfeld, Germany or Janvier SAS, St. Berthevin, France.
All animal care and experimental procedures were in concordance
with the German law on animal care and handling of animals and
the guidance of the European Community Council Directive, and
the protocol was approved by the local commission for the Care
and Use of Laboratory Animals of the Government by Baden-
Wu ¨rttemberg (Regierungspra ¨sidium Karlsruhe, permit numbers
35-9185.82/A-33/04 and 35-9185.82/A-31/04). All animals were
housed in plastic cages with water and food ad libitum and were
maintained on a 12 h light/dark cycle.
Drugs
Silexan, linalool, linalyl acetate, diazepam and pregabalin were
kindly provided by Dr. Willmar Schwabe GmbH & Co. KG,
Karlsruhe, Germany. Pentobarbital sodium salt, v-agatoxin IVA,
nifedipine, arachidonylethanolamide, pertussis toxin, geraniol, 1,8-
cineole and fura-2-AM were purchased from Sigma-Aldrich,
Taufkirchen, Germany. v-conotoxin GVIA was obtained from
Tocris Bioscience, Bristol, UK and dihydrolinalool from TCI
Europe, Eschborn, Germany. [
3H]-gabapentin was obtained from
Biotrend, Cologne, Germany.
Elevated Plus Maze test
Male NMRI mice (8 per group) were treated orally for 3 days
with doses between 1 and 30 mg/kg/day Silexan, 0.2% agar
suspension (10 ml/kg), diazepam (2.5 mg/kg) or pregabalin
(100 mg/kg) as positive controls. Anxiety-related behaviour was
tested 1 h after the last treatment in a standard elevated plus maze
apparatus (central platform 565 cm, open arms 3065 cm, closed
arms 3065615 cm), 60 cm above the floor. The number of
entries and the time spent in the open arms was recorded during 5
minutes.
Pentobarbital sleep time
Female NMRI mice were treated orally for 9 days with dosages
between 1 and 30 mg/kg Silexan, 0.2% agar suspension (10 ml/
kg) or pregabalin (100 mg/kg). Pentobarbital (45 mg/kg) was
diluted in physiological saline and administered i.p. to each mouse
one hour after last treatment. The sleeping time was defined as the
lapse of time required to change from dorsal position to the
normal position.
Isolation and plating of rat P0–P2 hippocampal neurons
Primary hippocampal neurons were prepared from P0–P2
Sprague-Dawley rat pups according to Amaral et al using the
Worthington Papain Dissociation Kit (Worthington, Lakewood,
NJ) [15]. Cells were plated on poly-D-lysine/laminin coated glass
cover slips in serum free Neurobasal A media containing L-
glutamine (1 mM) and 2% B27 in 6 well plates at a density of
2610
5 cells per well. Neurons were grown in 37uC in a humidified
incubator containing 5% CO2 in air. Cultures were maintained for
14 days before experimental procedures.
Calcium measurements in primary hippocampal neurons
Intracellular Ca
2+ measurements were conducted according to
literature [16,17]. After 14 days, hippocampal neurons on cover
slips were loaded with 1 mM fura-2-AM for 30 min and then
placed on the stage of an inverted Axiovert S100 microscope
(Zeiss, Oberkirchen, Germany). Intracellular calcium concentra-
tions were measured by dual excitation (340/380 nm) ratio
method.
Synaptosomal preparations for intracellular calcium
measurements
Murine synaptosomes from whole brain without cerebellum
were prepared as described previously [18]. Synaptosomal samples
were loaded with 5 mM fura-2-AM for 40 min. Fura-2-signals
were calibrated according to the method of Grynkiewicz et al,
using a KD value of 224 nM [19]. For the determination of Rmax
and Rmin 0,2% sodium dodecyl sulphate and tris(hydroxymethyl)
aminomethane (Tris) 30 mM/ethylene glycol bis(2-aminoethyl
ether)-N,N,N9N9-tetraacetic acid (EGTA) 6 mM, respectively
were added.
[
3H]-gabapentin binding studies
Partially purified synaptic membranes were prepared from
mouse cortex using sucrose density gradients according to Suman-
Chauhan et al [20]. Protein content of synaptic membrane
suspension was determined by the Lowry protein assay [21]. For
[
3H]-gabapentin binding studies, tissue (0.1 mg protein) was
incubated with 20 nM [
3H]-gabapentin in 10 mM HEPES buffer
(pH 7.4 at RT) in the presence of varying concentrations of test
compound for 40 min. Afterwards, the samples were filtered
through Whatman GF/B filters under vacuum. Filters were
washed 3 times with 5 ml ice-cold 100 mM NaCl. Bound
radioactivity was determined using liquid scintillation counting.
Non-specific binding was defined by 1 mM pregabalin.
Electrophysiological recordings
For measurement of N- and P/Q-type currents, different
transfected cell lines were applied, each expressing only one
VOCC subtype. N-type channel recordings were carried out on
CHO cells stably expressing Cav2.2, a2d-1 and b-subunits. The
Lavender Oil Modulates VOCCs
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e59998cell line was kindly provided by B. Fakler, Institute of Physiology
II, University of Freiburg, Germany. Cells were grown in Minimal
Essential Medium (MEM) ALPHA including 10% fetal calf serum,
L-glutamine 200 mM, G418 0.7 mg/ml, hygromycin B 0.25 mg/
ml and blasticidin 5 mg/ml. For P/Q-type current analysis, HEK
293 cells were transiently transfected with a2d-1 and b3a subunits,
as previously described, whereas the a1A subunit was cloned in a
pEGFP-N1 vector [22].
Whole cell calcium currents were recorded using the HEKA-10
patch clamp amplifier (HEKA Electronic, Lambrecht, Germany).
For measurement of calcium current inhibition by Silexan,
extracellular solution containing vehicle or Silexan was applied
by superfusion and currents were recorded at 1 Hz during a 50 ms
depolarizing pulse to 20 mV. The extracellular solution contained
(in mM): CaCl2 10, tetraethylammonium chloride (TEA-Cl) 125,
HEPES 10 and glucose 5. The pH was adjusted to 7.4 using TEA-
OH. The intracellular solution contained (in mM): CsCl 110,
HEPES 10, EGTA 10, MgCl2 3, Na-adenosine triphosphate (Na-
ATP) 3 and guanosine 5-triphosphate tris salt (GTP-Tris) 0.6. The
pH was adjusted to 7.2 using CsOH. Patch pipettes were pulled
from borosilicate glass tubing (Sutter Instruments, Novato, CA,
USA) with input resistance ranged between 1.8 and 4.0 MV. Cell
capacitance ranged between 12 and 25 pF for N-type cells and 10
and 50 pF for P/Q-type cells. Series resistance was typically
between 2.5 and 8 MV and was compensated up to 70%. Data
were recorded with HEKA pulse 8.5 software package and
analysed off-line. The holding potential in experiments with N- or
P/Q-type cells was 280 mV.
Statistical analysis
Results were expressed as mean 6 SEM. Statistical analyses
were performed with two-sided t-tests. Stars represent p-values:
***p,0.001, **p,0.01, *p,0.05.
Results
Silexan improves anxiolytic behaviour in the elevated
plus maze test
Several groups previously showed anxiolytic effects of LA
preparations given by inhalation not standardized concerning
their composition [6,7]. None of these studies dealt with anxiolytic
effects of oral administered LA in dosages which are in accordance
with the dosage of 80 mg/d used in humans. Therefore, we tested
the anxiolytic activity of Silexan in the elevated plus maze test, a
well established anxiety model. Mice were treated orally for 3 days
with Silexan, the benzodiazepine diazepam or the gabapentinoid
Figure 1. Silexan reduces anxiety-related behaviour in the elevated plus maze and increases pentobarbital-induced sleeping time.
(A–C) Mice were treated orally with diazepam (2.5 mg/kg BW), pregabalin (100 mg/kg BW) or Silexan (1–30 mg/kg BW) for three days. Diazepam,
pregabalin and Silexan increased the time spent in the open arm (A, B) and entry number (C). (D) Mice were treated orally with pregabalin (100 mg/
kg BW) or Silexan (1–30 mg/kg BW) for nine days. Sleeping time was determined after i.p. application of pentobarbital (45 mg/kg BW). All data
presented are mean values 6 SEM using 8 mice per treatment group (unpaired t-test).
doi:10.1371/journal.pone.0059998.g001
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pregabalin both increased the time spent in the open arm
(Fig. 1B and C) as well as the number of entries into the open arm.
Already at a concentration of 1 mg/kg BW Silexan showed a
significant elevation of the number of entries into the open arm
(Fig. 1A). This anxiolytic effect is dose-dependent and already
maximal at a concentration of 3 mg/kg BW. Similar to diazepam
and pregabalin, Silexan also elevated the pentobarbital sleeping
time (Fig. 1D) at similar concentrations (3–30 mg/kg) in accor-
dance with Linck et al [8]. As Silexan does not show sedation in
humans, this finding rather suggests sleep promoting than sedative
properties [9,10,23–26].
Similar effects of Silexan and pregabalin on VOCCs in
murine synaptosomes
Silexan showed no affinity to known targets of other anxiolytic
drugs such as SERT, NET, DAT, MAO-A and the GABAA-
receptor (data not shown). Therefore, we investigated if Silexan
shares its mode of action with the gabapentinoid pregabalin which
targets the a2d-1 and -2 subunits of VOCCs. We examined, if
Silexan and pregabalin inhibit Ca
2+-influx in murine synapto-
somes (Fig. 2A–C). VOCCs were activated by KCl. Under these
conditions pregabalin inhibited Ca
2+-influx substantially (Fig. 2A,
2C). Maximal effects were already seen at a concentration of 3 mM
reducing the Ca
2+-influx to 65.8666.71%. Increasing pregabalin
concentrations did not show any additional effect. Silexan dose-
dependently reduced KCl-induced Ca
2+-increase in a biphasic
mode, showing an inhibition of about 20% at concentrations
between 0.1 and 1 mg/ml(Fig. 2B, 2C). Contrary to pregabalin,
Silexan further decreased Ca
2+-elevation at higher concentrations,
exceeding pharmacologically relevant plasma levels in man and
animal by several orders of magnitude (data not shown). The
major ingredients of Silexan are linalool and linalyl acetate which
each make up to about 35% of the product. However, linalool and
linalyl acetate are similarly active when applied directly to the
synaptosomes (Fig. 2E). Due to the fact that linalyl acetate is
completely metabolized to linalool, we estimated an IC50 value for
linalool of about 37 nM (Fig. 2D).
One possible explanation for this effect could be a nonspecific
modulation of channels properties by alterations of membrane
fluidity. However, using the fluorescence probe 1,6-diphenyl-
1,3,5-hexatriene and mouse brain membranes according to Kirsch
et al. [27], no effect of Silexan on membrane fluidity was seem up
to concentrations of 100 mg/ml.
Figure 2. Silexan dose-dependently inhibits VOCCs in murine synaptosomes. Dose-dependent effects of pregabalin (A), Silexan (B) and
linalool (D) on KCl-induced Ca
2+-influx. Murine synaptosomes were preincubated (10 min) with different concentrations of pregabalin (A, 0.03–
100 mM), Silexan (B, 0.01–10 mg/ml) or linalool (D, 0.01–1 mM) and afterwards stimulated with KCl (80 mM). (C) Representative Ca
2+-transients in
murine synaptosomes after KCl-induced activation of VOCCs in the presence and absence of pregabalin (3 mM) and Silexan (1 mg/ml). (E) Effect of the
preincubation (10 min) with linalool (1 mM) and linalyl acetate (1 mM) on KCl-induced Ca
2+-influx in murine synaptosomes. (F) Several other
monterpenes have no effect on KCl-induced Ca
2+-influx in murine synaptosomes under similar conditions. All data presented are mean values 6 SEM
(n=10–12), paired t-test.
doi:10.1371/journal.pone.0059998.g002
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effects on VOCCs are selective, we additionally investigated
several terpenes with closely related chemical structures such as
geraniol, cineol and dihydrolinalool. Importantly, none of the
other terpenes inhibited KCl induced calcium influx (Fig. 2F)
supporting the idea that this effect is specific for linalool and
lavender oil and is not a common phenomenon of lipophilic
monoterpenes.
Silexan also inhibits VOCCs in primary hippocampal
neurons
To further characterize the effects of Silexan on VOCCs, we
decided to study KCl dependent Ca
2+-influx in primary hippo-
campal neurons because of the important role of the hippocampus
for regulating emotions and anxiety. Similar to the effects obtained
in synaptosomes, Silexan inhibited significantly and dose-depen-
dently KCl induced Ca
2+-increase (Fig. 3A, C, D, G) in
concentrations between 0.1 and 30 mg/ml. In this model,
pregabalin decreased Ca
2+ currents to 62.8468.64% of ctl
(30 mM; Fig.3B, C, E, H).
Silexan does not bind to the gabapentin binding site at
a2d-subunits of P/Q-type VOCCs
The specific effects of pregabalin and the structurally related
drug gabapentin on presynaptic VOCCs of the P/Q-type have
been associated with the specific binding to the modulating and
partially extracellularly located subunit a2d-1 and -2, which can
be labelled by [
3H]-gabapentin binding [13,28]. In agreement
with the literature pregabalin inhibited specific [
3H]-gabapentin
binding with an IC50 value of about 70 nM (Fig. 4A) [29]. In
contrast, no effect on [
3H]-gabapentin binding was observed for
Silexan (Fig. 4B). Thus, even if both drugs seem to interact with
VOCCs, they probably do not share the same binding site at
VOCCs.
Figure 3. Silexan and pregabalin show similar inhibitory effects on VOCCs in primary hippocampal neurons. Concentration-dependent
effect of Silexan (A, 0.01–10 mM) and pregabalin (3–30 mM) after 10 min preincubation on KCl (60 mM) induced Ca
2+-influx in primary hippocampal
neurons. (C) shows representative traces of intracellular Ca
2+ concentration in primary hippocampal neurons stimulated with KCl (60 mM)
preincubated with Silexan (1 mg/ml), pregabalin (10 mM) compared to ctl. (D)–(F) show representative fields of fura-2 loaded hippocampal neurons
preincubated with Silexan 1 mg/ml (D), pregabalin 10 mM (E) or control (F) under basal conditions. (G)–(I) show the same samples after stimulation
with KCl (60 mM). All data presented are means 6 SEM (n=10–14, paired t-test).
doi:10.1371/journal.pone.0059998.g003
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VOCCs inhibition by Silexan
Modulation of VOCCs could either occur via direct action on
the VOCC protein complex or indirect via activation of upstream
Gi coupled receptors, e.g. cannabinoid receptors [30]. We
measured KCl-induced Ca
2+-elevation in primary hippocampal
neurons treated with Silexan in the presence or absence of
pertussis toxin (PTX). PTX specifically and irreversibly inactivates
Gi protein coupled receptors via catalysis of Gai subunit ADP-
ribosylation [31]. Silexan reduced significantly depolarisation
induced Ca
2+- influx independent of PTX treatment (Fig. 4C).
Arachidonylethanolamide was used as positive control. The
endogenous ligand for the CB1 cannabinoid receptor decreased
KCl-induced Ca
2+-influx to 44.2669.37% [32]. Due to Gi protein
involvement, the inhibitory effect was almost completely abolished
after PTX treatment (91.28616.22%). Taken together, Silexan
does not interact with Gi coupled G-protein coupled receptors.
Silexan inhibits different classes of VOCCs
To elucidate if Silexan preferentially inhibits P/Q type VOCCs
such as pregabalin, we deternined the effects of Silexan in the
presence of the P/Q type inhibitor v-agatoxin IVA and the N-
type inhibitor v-conotoxin GVIA because these two channel types
mainly promote the KCl mediated Ca2+-increase in primary
hippocampal and in synaptosomes (please also see Supplementary
Figure S1).
Both toxins used in this study target ligand-binding pockets at
the a1 subunit and have been reported to act additively [33,34].
This was confirmed in our experiments. After single toxin
incubation, v-agatoxin IVA reduced KCl-induced Ca
2+-elevation
to 65.0268.88%, while v-conotoxin GVIA diminished Ca
2+-
currents to 68.4463.16%. Joint application of the two toxins
lowered KCl-evoked increase in intrasynaptosomal Ca
2+-concen-
trations to 40.4363.55% (Fig. 4D). To test if Silexan acts
specifically at a single VOCC subtype, we performed combined
application measurements with v-conotoxin GVIA (30 nM;
Fig. 4E) or v-agatoxin IVA (100 nM; Fig. 4F). When both toxins
were applied together with Silexan, no relevant additive effects
were observed. This observation strongly argues against a specific
effect of Silexan at one of the individual VOCCs.
This last observation prompted us to further investigate the
effects of Silexan on the properties of VOCCs using the patch-
clamp technique. In CHO cells stably expressing N-type VOCC,
Silexan displayed a concentration-dependent inhibition of Ca
2+
currents (Fig. 5A/C/D). Silexan 1 mg/ml already reduced Ca
2+
currents significantly by about 10%. At the higher concentration
of 10 mg/ml Ca
2+ currents were additionally inhibited to about
80%. The currents recover after washing out Silexan 1 mg/ml and
Figure 4. Silexan does neither share the binding site of pregabalin, nor inhibits VOCCs via Gi-coupled receptors. (A) Displacement
studies conducted with [
3H]-gabapentin in partially purified synaptic membranes. Synaptic membranes were incubated with [
3H]-gabapentin in
presence of pregabalin (A, 0.001–100 mM) or Silexan (B, 0.1–100 mM; n=3). (C) Primary hippocampal neurons were incubated in the presence or
absence of PTX (200 ng/ml) for 18 h. Afterwards cells were treated with Silexan (1 mg/ml) or AEA (1 mM) for 10 min and then stimulated with KCl
(60 mM; n=11–12). (D) Additive inhibitory effects of P/Q-type and N-type channel blockers on KCl-induced Ca
2+-influx in murine synaptosomes.
Synaptosomes were preincubated with v-agatoxin IVA (100 nM), v-conotoxin GVIA (30 nM) or a combination of both inhibitors for 10 min.
Afterwards, they were stimulated with KCl (80 mM). Silexan (1 mg/ml) causes no significant additive effects when combined with the N-type VOCCs
inhibitor v-conotoxin GVIA (30 nM, E), or the P/Q-type inhibitor v-agatoxin IVA (100 nM, F; n=9–12). All data presented are mean values 6 SEM
(paired t-test).
doi:10.1371/journal.pone.0059998.g004
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could be demonstrated in transiently transfected HEK 293 cells,
expressing the P/Q-type channel (Fig. 5B). Silexan caused a
reduction of Ca
2+ currents in P/Q-type expressing cells to a
similar extent and in a similar dose-dependent fashion. Electro-
physiological recordings in HEK 293 cells stably expressing the T-
type VOCC revealed that Silexan also inhibits low voltage
activated currents at this channel (data not shown). Taken
together, our findings suggest that Silexan acts non-specifically at
different classes of VOCC.
Discussion
In the past, several mechanisms for lavender oil’s beneficial
effects on anxiety and mood were postulated, including interac-
tions with NMDA or GABAA receptors, voltage dependent
sodium channels, or glutamatergic and cholinergic neurotrans-
Figure 5. Silexan inhibits N- and P/Q-type VOCCs in whole cell patch-clamp experiments. (A) Whole cell recordings of N-type VOCCs were
conducted in CHO cells stably expressing N-type Ca
2+ channels. Silexan (1 or 10 mg/ml) was applied by superfusion for 50 s. The cells were stimulated
with a depolarizing pulse to 20 mV at 1 Hz and the amplitude was recorded (n=9–14). (C, D) Representative currents of whole cell patch clamp
recordings with Silexan 1 and 10 mg/ml in N-type cells when stimulated with a depolarizing pulse to 20 mV before (ctl) and at the end of Silexan
application (+ Silexan). (B) Effect of preincubation of Silexan (1–10 mM) on depolarizing pulses to 20 mV in P/Q-type cells (n=4–5). (E and F) Time
course of the N-type Ca2+ channel peak current amplitude for 125 seconds by depolarizing pulses to +20 mV at a pulse frequency of 1 Hz. Inhibition
of the N-type Ca2+ channel peak current amplitude by Silexan 1 mg/ml (E) or 10 mg/ml (F) compared to DMSO. The arrows indicate the time points of
the Silexan application and the washout. A total number of 10 (DMSO), 14 (Silexan 1 mg/ml) and 9 cells (Silexan 10 mg/ml) were averaged. All data
presented are mean values 6 SEM (unpaired t-test).
doi:10.1371/journal.pone.0059998.g005
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millimolar or high micromolar concentration range.
Here we show three novel findings. First, Silexan shows
anxiolytic effects in the elevated plus maze test at low oral doses
(1–10 mg/kg BW) corresponding to dosages given in humans
(80 mg/d). Second, our studies revealed an inhibition of VOCCs
by Silexan at nanomolar concentrations. Third, pregabalin and
Silexan do not share the molecular target, the a2d subunit of P/Q
type channels [13,40]. In addition, Silexan did not inhibit Ca
2+-
increase via VOCCs as a consequence of previous activation of Gi
coupled receptors. Silexan unselectively modulates with similar
potency several VOCCs such as the N-type and the P/Q type
VOCCs. This parallels to some extent pregabalin, which acts on
the VOCC channel complex via the a2d subunit but mainly
inhibits P/Q type calcium channels. The precise mechanisms of
the channel modulation by Silexan are not yet known but may be
either direct by binding and inhibiting the channel complex or
more indirect by influencing the properties or surface expression of
VOCC subunits.
Taken together, we shed light into the molecular mechanism of
action of LA in anxiety and thereby might help to further establish
the clinical use of Silexan in patients suffering from anxiety.
Supporting Information
Figure S1 Similar expression pattern of VOCCs in
murine synaptosomes and primary hippocampal neu-
rons. m Murine synaptosomes (A–C) and primary hippocampal
neurons (D–F) were preincubated with the selective P/Q type
blocker v-agatoxin IVA (A/D), the selective N type blocker v-
conotoxin GVIA (B/E) and the L type blockers verapamil and
nifedipine (C/F) and afterwards stimulated with KCl. All data
represent mean 6 SEM (n=8–12; paired t-test). (G)–(J) Repre-
sentative confocal images of primary hippocampal neurons stained
with a specific primary antibody against P/Q-type VOCCs (G), N-
type VOCCs (H), and L-type VOCCs (I,J).
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